CClinicalTrials.gg
Status unknownNCT05123924Updated Nov 17, 2021

Respiratory Functions in Pediatric-Onset Multiple Sclerosis

An observational study in Pediatric-onset Multiple Sclerosis, sponsored by Istanbul University - Cerrahpasa. Status unknown at 1 site in Turkey. Open to participants aged 15 Years to 22 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Istanbul University - Cerrahpasa · Observational

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
46
Ages
15 Years to 22 Years
Sex
All
01

Study summary

Pediatric-onset multiple sclerosis (POMS) is a chronic, autoimmune and inflammatory disease of the central nervous system that begins before the age of 18 years. POMS patients are affected in terms of physical capacity, cognitive status and fatigue compared with their healthy peers that has been reported. It has been reported that although individuals with MS with low disability levels do not have respiratory complaints, respiratory parameters may be affected. Therefore, it is necessary to evaluate respiratory capacity, respiratory muscle strength and fatigue levels of POMS patients. Evaluations will help prevent future complications by detecting any existing problems early.

Read the detailed description

People with pediatric onset multiple sclerosis (POMS) may experience sensory, motor, cerebellar and cognitive dysfunctions due to the destruction of the central nervous system. These disorders can cause decrease in physical capacity, increase in cognitive symptoms and fatigue level in patients with POMS. There is no study in the literature examining the relationship between respiratory capacity and respiratory muscle strength with fatigue in POMS patients. The aim of this study is to compare POMS patients and healthy controls in terms of respiratory capacity, respiratory muscle strength and fatigue. All participants's respiratory function will be evaluated with "Minispir Light Spirometer", respiratory muscle strength with "MD Diagnostics RP Check" and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale. Evaluations will not be repeated after a certain interval.As a result of the comparison of both groups, it will be determined whether POMS patients have difficulties or not.

02

Conditions studied

  • Pediatric-onset Multiple Sclerosis

Keywords

  • Pediatric-onset multiple sclerosis
  • Physiotherapy
  • Respiratory capacity
  • Fatigue
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's planned enrollment of 46 is below the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 680 studies on the registry; 208 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Thirty patients with POMS who were diagnosed with pediatric-onset multiple sclerosis and met the inclusion criteria will be included in the study. Sample size, Gravesande et al. According to the child form in the PedsQL Multidimensional Fatigue Questionnaire, which they used in their study, according to the total fatigue scores (difference Δ 10.21), in POMS patients (61.57±20.78) and healthy individuals of the same age group (71.78±15.58), with 0.05 margin of error and 80% power. calculated. According to this calculation, it was seen that 25 patients with POMS and 13 healthy individuals who were matched for age and sex (2:1 distribution) should be included in our study.

Inclusion criteria

  • Volunteer to participate
  • Being diagnosed with pediatric onset multiple sclerosis
  • Being between the ages of 15-22
  • EDSS \<6

Exclusion criteria

Exclusion Criteria:

  • Having another diagnosis in addition to the diagnosis of pediatric-onset multiple sclerosis
  • Having a blurred vision problem
  • Having had an attack or received corticosteroid treatment 3 months before participating in the study
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
46 participants (estimated)
Patient registry
No

Groups and cohorts

  • POMS Group

    Individuals in the POMS group will be evaluated in terms of respiratory capacity, respiratory muscle strength and fatigue.

    Other: Evaluation of respiratory capacity, respiratory muscle strength and fatigue

  • Control Group

    Individuals in the control group will be evaluated in terms of respiratory capacity, respiratory muscle strength and fatigue.

    Other: Evaluation of respiratory capacity, respiratory muscle strength and fatigue

Interventions

  • OtherEvaluation of respiratory capacity, respiratory muscle strength and fatigue

    The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with "Minispir Light Spirometer", respiratory muscle strength with "MD Diagnostics RP Check" and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time.

06

What researchers measure

Primary outcomes

  1. Evaluation of FEV1/FVC ratio

    The Minispir Light Spirometer will be used to assess the respiratory function of the participants. Before starting the spirometric test, how to do the test will be explained. Before starting the test, the participant will be asked to sit with their back straight and put on the nose clip provided. Then the participant will take the disposable bacterial filter mouthpiece between his lips and hold it tightly. The person will be asked to take a few normal breaths followed by as deep a breath as possible and instructed to exhale forcefully and quickly without waiting. The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds. If the participant will coughs or cannot breathe deeply enough during the test, the test will terminated and the test will repeated after 20 minutes of rest. The FEV1/FVC ratio with the highest value from three consecutive correctly performed tests will be recorded.

    Time frame: Baseline

Secondary outcomes

  1. Evaluation of Forced Vital Capacity (FVC)

    The Minispir Light Spirometer will be used for FVC evaluation. Before starting the test, it will be explained how to do the test. The participant will be asked to sit with their back straight and put on the nose clip provided. Then the participant will take the disposable bacteria filter mouthpiece between his lips and holds it tightly. The person will be asked to take a few normal breaths, then take as deep a breath as possible, and then exhale forcefully and quickly without waiting. The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds. If the participant coughs or cannot breathe deeply enough during the test, the test is terminated and the test is repeated after 20 minutes of rest. The highest FVC value from three correctly performed consecutive tests will be recorded.

    Time frame: Baseline

  2. Evaluation of Forced Expiratory Volume in 1 second (FEV1)

    The Minispir Light Spirometer will be used for FEV1 evaluation. Before starting the test, it will be explained how to do the test. The participant will be asked to sit with their back straight and put on the nose clip provided. Then the participant will take the disposable bacteria filter mouthpiece between his lips and holds it tightly. The person will be asked to take a few normal breaths, then take as deep a breath as possible, and then exhale forcefully and quickly without waiting. The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds. If the participant coughs or cannot breathe deeply enough during the test, the test is terminated and the test is repeated after 20 minutes of rest. The highest FEV1 value from three correctly performed consecutive tests will be recorded.

    Time frame: Baseline

  3. Evaluation of Peak Expiratory Flow (PEF)

    The Minispir Light Spirometer will be used for PEF evaluation. Minispir Light Spirometer will be used for PEF evaluation. Before starting the test, it will be explained how to do the test. The participant will be asked to sit with their back straight and put on the nose clip provided. Then the participant will take the disposable bacteria filter mouthpiece between his lips and holds it tightly. The person will be asked to take a few normal breaths, then take as deep a breath as possible, and then exhale forcefully and quickly without waiting. The test will be terminated by instructing the participant to take a deep breath after exhaling for at least six seconds. If the participant coughs or cannot breathe deeply enough during the test, the test is terminated and the test is repeated after 20 minutes of rest. The highest PEF value from three correctly performed consecutive tests will be recorded.

    Time frame: Baseline

  4. Evaluation of Respiratory Muscle Strength

    Evaluation of respiratory muscle strength will be done with the "MD Diagnostics RP Check" device in accordance with the guidelines of the American Thoracic Society (ATD) and the European Respiratory Society (ASD). The maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) of each participant will be measured. Before starting the test, it will be explained how to do the test. During the assessment, the participant will be asked to sit with his back straight and put on the nose clip provided. Then, for the MEP evaluation, the patient will be asked to take a deep breath and blow the whole breath forcefully into the device with a disposable bacteria filter mouthpiece. For the MIP evaluation, the patient will be asked to breathe strongly through the device with a disposable bacteria filter mouthpiece after exhaling the whole breath. Appropriate breaks will be given between assessments. Three correctly performed attempts for MEP and MIP measurements will be recorded.

    Time frame: Baseline

  5. Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale

    The Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale is a valid and reliable scale for assessing fatigue in the pediatric population. This 18-item symptom-focused scale evaluates 3 areas of fatigue (general, sleep/rest, and cognitive). Each question is scored on a 5-point Likert system (0=Never, 1=Almost never, 2=Sometimes, 3=Frequently, 4=Always), and high scores indicate higher levels of fatigue. In our study, both the child form and the family form of the scale will be used.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Istanbul University-Cerrahpasa
    Istanbul, Bakırköy 34100, Turkey
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05123924
Lead sponsor
Istanbul University - Cerrahpasa
Responsible party
Yonca Zenginler Yazgan (Principal Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Nov 17, 2021
Start date
Oct 29, 2021
Primary completion
Jun 2022 (estimated)
Completion
Jul 2022 (estimated)
Last update
Nov 17, 2021

Study contacts

Yonca Zenginler Yazgan, PhD
Contact
yoncazenginler@gmail.com
Pelin Vural, MSc.
Contact
pelinvural7@gmail.com
+905344245350
Buket Akıncı, Assoc. Prof.
study chair · Biruni University
Pelin Vural, MSc.
study chair · Istanbul University-Cerrahpasa, Graduate Education Institute
Serhat Güler, MD
study chair · Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Pediatric Neurology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion